The HCV Treatment Revolution Continues: Resistance Considerations, Pangenotypic Efficacy, and Advances in Challenging Populations

Gelijkaardige items

• Anemia Management in the Era of Triple Combination Therapy for Chronic HCV
  door: Jacobson, Ira M., et al.
  Gepubliceerd in: (2012)
• Treatment Options for HCV Nonresponders and Relapse Patients
  door: Pearlman, Brian L., et al.
  Gepubliceerd in: (2010)
• Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients
  door: Maughan, A., et al.
  Gepubliceerd in: (2019)
• A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From the 2016 EASL Meeting: The Annual Meeting of the European Association for the Study of the Liver • April 13–17, 2016 • Barcelona, Spain Special Reporting on: • Six Weeks of Sofosbuvir/Ledipasvir (SOF/LDV) Are Sufficient to Treat Acute Hepatitis C Virus Genotype 1 Monoinfection: The HepNet Acute HCV IV Study • Treatment of Hepatitis C Virus in Patients With Advanced Cirrhosis: Always Justified? Analysis of the HEPA-C Registry • High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 in Previously Treated Patients With HCV Genotypes 1 Through 6 • Prevalence and Impact of Baseline Resistance-Associated Variants (RAVs) on the Efficacy of Ledipasvir/Sofosbuvir or Simeprevir/Sofosbuvir Against GT1 HCV Infection: HCV-TARGET Interim Analysis • Sofosbuvir/Velpatasvir for 12 Weeks in Patients Coinfected With HCV and HIV-1: The ASTRAL-5 Study • 100% SVR12 With ABT-493 and ABT-530 With or Without Ribavirin in Treatment-Naive HCV Genotype 3–Infected Patients With Cirrhosis PLUS Meeting Abstract Summaries With Expert Commentary by: Steven L. Flamm, MD Chief, Liver Transplantation Program Professor of Medicine and Surgery Northwestern University Feinberg School of Medicine Chicago, Illinois
  Gepubliceerd in: (2016)
• A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection from The Liver Meeting 2013: The 64th Annual Meeting of the American Association for the Study of Liver Diseases November 1-5, 2013 • Washington DC Special Reporting on: • Simeprevir plus Sofosbuvir with or without Ribavirin Produces High SVR Rates in Genotype 1 HCV Infection • Novel Interferon- and Ribavirin-Free Regimen Results in SVR12 Rates of Over 90% in HCV Genotype 1b Infection • Studies Confirm Efficacy of Adjunctive Simeprevir in Difficult-to-Treat HCV Genotype 1 Subpopulations • All-Oral Therapy with Sofosbuvir Plus Ribavirin Produces High SVR Rates in Patients Coinfected with HCV and HIV • Faldaprevir Combined with Pegylated Interferon and Ribavirin Demonstrates High Efficacy in DifficuIt-to-Treat HCV Infection • Once Daily Sofosbuvir/Ledipasvir Combination Elicits Rapid Decline in HCV RNA PLUS Meeting Abstract Summaries With Expert Commentary by: Ira M. Jacobson, MD Weill Cornell Medical College New York, New York
  Gepubliceerd in: (2014)